These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 1464420)
1. Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besançon experience. Herve P; Racadot E; Wendling D; Rumbach L; Tiberghien P; Cahn JY; Flesch M; Wijdenes J Immunol Rev; 1992 Oct; 129():31-55. PubMed ID: 1464420 [No Abstract] [Full Text] [Related]
2. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation. Herve P; Bordigoni P; Cahn JY; Flesch M; Tiberghien P; Racadot E; Milpied N; Bergerat JP; Plouvier E; Roche C Transplant Proc; 1991 Feb; 23(1 Pt 2):1692-4. PubMed ID: 1989333 [No Abstract] [Full Text] [Related]
3. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor. Tiley C; Powles R; Teo CP; Treleaven J; Findlay M; Hewetson M Bone Marrow Transplant; 1991; 7 Suppl 2():151. PubMed ID: 1652326 [No Abstract] [Full Text] [Related]
4. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909 [TBL] [Abstract][Full Text] [Related]
5. Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563). Hertenstein B; Stefanic M; Sandherr M; Bunjes D; Mertens T; Arnold R Transplant Proc; 1994 Dec; 26(6):3114-6. PubMed ID: 7998086 [No Abstract] [Full Text] [Related]
6. Prevention of acute graft-versus-host disease by monoclonal antibody to interleukin-2 receptor. Blaise D; Maraninchi D; Mawas C; Stoppa AM; Hirn M; Guyotat D; Attal M; Reiffers J Lancet; 1989 Jun; 1(8650):1333-4. PubMed ID: 2566864 [No Abstract] [Full Text] [Related]
7. [Immunomodulating therapy of rheumatoid arthritis (chronic polyarthritis): use of monoclonal antibodies]. Horneff G; Burmester GR Z Rheumatol; 1995; 54(2):96-104. PubMed ID: 7540786 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody. Hervé P; Racadot E; Wijdenes J; Flesch M; Tiberghien P; Bordigoni P; Holler E; Powles M; Bourdeau M; Wilmer E Bone Marrow Transplant; 1991; 7 Suppl 2():149. PubMed ID: 1878688 [No Abstract] [Full Text] [Related]
9. Treatment of acute graft-versus-host disease with monoclonal antibody to IL-2 receptor. Hervé P; Wijdenes J; Bergerat JP; Milpied N; Gaud C; Bordigoni P Lancet; 1988 Nov; 2(8619):1072-3. PubMed ID: 2903293 [No Abstract] [Full Text] [Related]
10. Perspectives in the prevention and treatment of acute graft versus host disease. Herve P Bone Marrow Transplant; 1991; 7 Suppl 2():117-9. PubMed ID: 1715225 [No Abstract] [Full Text] [Related]
11. [Clinical applications of monoclonal antibodies]. Boucheix C Rev Med Interne; 1985 Oct; 6(4):403-10. PubMed ID: 3906817 [No Abstract] [Full Text] [Related]
12. Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis. Kyle V; Coughlan RJ; Tighe H; Waldmann H; Hazleman BL Ann Rheum Dis; 1989 May; 48(5):428-9. PubMed ID: 2786388 [TBL] [Abstract][Full Text] [Related]
13. A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study. Wijdenes J; Beliard R; Muot S; Herve P; Peters A Dev Biol Stand; 1990; 71():103-11. PubMed ID: 2205522 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic approaches with monoclonal antibodies to immunological diseases. Cozzi E; Ferrone S Recenti Prog Med; 1992 Sep; 83(9):528-33. PubMed ID: 1439123 [TBL] [Abstract][Full Text] [Related]
15. T-cell depletion with the monoclonal antibody Campath 1 to prevent graft-versus-host disease in ten high-risk adult patients. Bandini G; Ricci P; Gobbi M; Tazzari PL; Motta MR; Guardigli C; Rizzi S; Baccarani M; Tura S Haematologica; 1986; 71(4):307-11. PubMed ID: 3096824 [No Abstract] [Full Text] [Related]
16. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Martin PJ; Pei J; Gooley T; Anasetti C; Appelbaum FR; Deeg J; Hansen JA; Nash RA; Petersdorf EW; Storb R; Ghetie V; Schindler J; Vitetta ES Biol Blood Marrow Transplant; 2004 Aug; 10(8):552-60. PubMed ID: 15282533 [TBL] [Abstract][Full Text] [Related]
17. Use of an anti-interleukine 2 receptor monoclonal antibody for GvHD prophylaxis in unrelated bone marrow transplantation. GEGMO Group. Belanger C Bone Marrow Transplant; 1993; 11 Suppl 1():112-3. PubMed ID: 8448532 [No Abstract] [Full Text] [Related]
18. [Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?]. Larghero J; Vija L; Lecourt S; Michel L; Verrecchia F; Farge D Rev Med Interne; 2009 Mar; 30(3):287-99. PubMed ID: 18930338 [TBL] [Abstract][Full Text] [Related]